Eterna Therapeutics

ERNAPre-clinical

Eterna Therapeutics is focused on developing transformative mRNA-based cell engineering technologies to create a new generation of cellular medicines. The company's core platform enables precise, in vivo cell reprogramming and gene editing to treat a range of serious diseases. As a publicly traded entity, Eterna is advancing multiple preclinical programs while exploring strategic partnerships to accelerate its pipeline development.

Market Cap

$7.2M

Focus

Biotech

ERNA · Stock Price

USD 0.27626.73 (-99.96%)

Historical price data

AI Company Overview

Technology Platform

Proprietary mRNA and gene editing platforms for in vivo cell reprogramming and engineering, focused on creating hypoimmune (immune-evasive) cell therapies.

Funding History

Total raised: $128M

IPO$75MUndisclosedFeb 15, 2021

Series A$53MMPM CapitalAug 15, 2020

Opportunities

The company has significant growth potential in the large and expanding market for allogeneic cell therapies and in vivo reprogramming.

Successfully demonstrating proof-of-concept for its hypoimmune platform could attract major pharmaceutical partnerships and significantly increase its valuation.

Risk Factors

Key risks include the high technical and clinical failure risk inherent in novel platform technologies, dependence on volatile capital markets for funding as a pre-revenue company, and intense competition from larger, better-funded biotechs and pharma companies.

Competitive Landscape

Eterna competes with large biopharma (Vertex, Bayer/BlueRock) and specialized biotechs (Sana Biotechnology, CRISPR Therapeutics, Fate Therapeutics) in cell engineering. Its differentiation lies in its specific mRNA-based approach to creating immune-evasive cells for off-the-shelf therapies.